Enhancement of contract services for genetically modified mice using CRISPR/Cas9 genome-editing technology
First written in FY2016. 4 of 12 entries say "Restated". Latest entry: 2026-03-25.
No other company in this theme has enough history to compare yet.
- 2026-03-25ReframedOccurring Fact
「We will shift away from our previous earnings structure centered on contract production of genetically modified mice for academic institutions. Going forward, we will make pharmaceutical companies and drug-discovery ventures our primary customers and transition to a business model centered on consulting for high-value-added studies, including preclinical studies using genetically modified mice, and the supply of model mice, thereby strengthening our earnings base.」
The genetically modified mouse business is shifting its focus from a revenue structure centered on contract production for academic institutions to a business model centered on high-value-added studies, consulting, and the supply of model mice for pharmaceutical companies and drug-discovery ventures. - FY2021ReframedAnnual report
「In April 2021, we transferred the genetically modified mouse business to 安評センター and the antibody business to 医化学創薬株式会社, consolidating the Group's management resources and establishing a structure focused more closely on developing high-value-added services.」
The genetically modified mouse business changed from the Company to 安評センター, shifting the focus from strengthening contract services based solely on existing technologies to developing high-value-added services combined with testing services within the Group. - FY2020ReframedAnnual report
「For the production and sale of genetically modified mice, we will shift our customer base from one centred on academic researchers to one centred on companies with needs extending beyond mouse production to related experiments, in response to changes in the business environment, including technological innovations that enable academic researchers to produce genetically modified mice themselves. We will also pursue Group synergies by expanding the business beyond the production and sale of genetically modified mice to include preclinical studies using them.」
The focus has shifted from the previous explanation centred specifically on the use of CRISPR/Cas9 to moving the customer base toward companies in response to the wider adoption of the technology and expanding the business scope to related experiments and preclinical studies. - FY2019RestatedAnnual report
「In response to changing demand for genetically modified mice resulting from advances in genome-editing technology, we have worked on introducing and evaluating technologies to provide more advanced genetic modification methods as services.」
The Company continues to work on commercialising more advanced genetic modification methods as services in response to advances in genome-editing technology. - FY2018-Q3AdvancedAnnual report
「The Company entered into a license agreement with Tokyo Medical and Dental University for non-exclusive rights in Japan to use patents covering a highly efficient CRISPR/Cas9 knock-in method. The method enables the efficient introduction of point mutations and large recombination events in fertilised eggs, which had previously been difficult to achieve.」
The Company entered into a license agreement with Tokyo Medical and Dental University for non-exclusive rights in Japan to use a highly efficient CRISPR/Cas9 knock-in method. - FY2018-Q2RestatedAnnual report
「Against this backdrop, in the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while making upfront investments, including additional personnel in both manufacturing and sales, to expand order capacity.」
The Company continues to describe its policy of pursuing orders for contract production of genetically modified mice using CRISPR/Cas9 and expanding order capacity in both manufacturing and sales. - FY2018-Q1RestatedAnnual report
「Against this backdrop, in the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while making upfront investments, including additional personnel in both manufacturing and sales, to expand order capacity.」
The Company continues to pursue orders for contract production of genetically modified mice using CRISPR/Cas9. - FY2017AdvancedAnnual report
「Building on the momentum from orders for "production of genetically modified mice using genome-editing technology (CRISPR/Cas9)," conducted under a non-exclusive license from the US Broad Institute, exceeding plan, we will work to expand orders further.」
The Company reports concrete progress, with orders for genetically modified mice produced using CRISPR/Cas9 exceeding plan, and is moving toward further order growth. - FY2017-Q3AdvancedAnnual report
「Against this backdrop, in the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while working to improve the efficiency of fixed costs, including labour costs.」
Contract production of mice using CRISPR/Cas9 continued to perform well, with the genomics business recording sales of ¥280.954 million and operating profit of ¥67.113 million. Operating profit increased 330.0% year on year. - FY2017-Q2AdvancedAnnual report
「In the genomics business, the Group focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while working to improve the efficiency of fixed costs, including labour costs.」
Contract production of mice using CRISPR/Cas9 performed well, resulting in genomics business sales of ¥182.125 million and operating profit of ¥52.627 million. The disclosure describes concrete results from using the technology to generate orders. - FY2017-Q1RestatedAnnual report
「In the genomics business, we focused on orders using genome-editing technology (CRISPR/Cas9), which can shorten production times and further reduce costs for contract services for genetically modified mice, while working to improve the efficiency of fixed costs, including labour costs.」
The Company continues to target stronger orders for contract production of genetically modified mice using CRISPR/Cas9. - FY2016First statedAnnual report
「In April last year, we obtained a non-exclusive license to a portfolio of patents held by the US Broad Institute relating to genome-editing technology (CRISPR/Cas9) that can shorten the production period for contract services for genetically modified mice, and worked to strengthen orders.」
The Company obtained a license for CRISPR/Cas9 technology expected to shorten production times and is working to translate it into stronger orders.